Cervical hyperaesthesia in dogs: an epidemiological retrospective study of 185 cases.

OBJECTIVES: To describe the prevalence, clinical findings and predictors of disease in dogs with cervical hyperaesthesia. MATERIALS AND METHODS: Medical records of dogs referred for neurological investigation of cervical hyperaesthesia between 2009 and 2013 were retrospectively reviewed. Dogs were assigned to one of the following groups according to the final diagnosis: Non-Neurologic, Brain, Cervical Spine, Multifocal, and Chiari-like Malformation/Syringomyelia. Demographic data, clinical and neurological signs and laboratory findings were compared between groups using univariate analysis; predictors of disease location were assessed by multivariate analysis. RESULTS: Final diagnostic allocations of the 185 records included in the study were as follows: 2.7% Non-Neurologic, 2.2% Brain, 63.2% Cervical Spine, 22.2% Multifocal and 9.7% Chiari Malformation/Syringomyelia. Intervertebral disc extrusion and steroid-responsive meningitis arteritis were the most common diseases. Compared to Multifocal dogs, those allocated a Cervical Spine diagnosis were older, heavier, more frequently ataxic and lame on a thoracic limb; furthermore, they were less frequently depressed or hyperthermic at presentation. Leucocytosis, neutrophilia and monocytosis were more frequent in dogs allocated a Multifocal diagnosis. Dogs with cervical hyperaesthesia older than 36 months and non-hyperthermic at presentation were more likely to have a lesion of the cervical region rather than a multi-focal disease. CLINICAL SIGNIFICANCE: Although non-specific, these results may be useful to guide clinicians in management of dogs presenting with cervical hyperaesthesia. Animal age and body temperature may support the suspicion of either focal or multi-focal cervical spinal disease.

Effect of a randomised controlled vitamin D trial on insulin resistance and glucose metabolism in patients with type 2 diabetes mellitus.

The aim of our study was to investigate the influence of a 6-month vitamin D supplementation in patients with noninsulin-requiring type 2 diabetes mellitus. We included 86 patients in a placebo-controlled, randomised, double-blind study. During 6 months patients received Vigantol oil once a week corresponding to a daily dose of 1904 IU or placebo oil, followed by 6 months of follow-up. At start and at 3-month intervals 25OHD, PTH, body mass index, HbA1c, insulin, C-peptide, and homeostasis model assessment-index were measured. The primary outcome was a change in fasting blood glucose and insulin levels. After 6 months of therapy, the verum group's 25OHD had increased to a median of 35 ng/ml in comparison to the placebo group (median 20 ng/ml, p<10-6). PTH tended to decrease in the verum group (25.5 pg/ml vs. 35.0 pg/ml, p=0.08). After 6 months of therapy, 31 patients (78%) achieved a 25OHD concentration of >20 ng/ml. Their HbA1c was significantly lower at baseline (p=0.008) and after therapy (p=0.009) than in patients with 25OHD below 20 ng/ml. C-Peptide, insulin, and HOMA-index did not change significantly in the verum group but fasting insulin was positively correlated with 25OHD concentrations after 6 months of therapy in both groups. There were no significant effects of vitamin D with a daily dose of 1904 IU on metabolic parameters in type 2 diabetes. However, the correlative findings of this study suggest a link of the 25OHD status and metabolic function in type 2 diabetes. Whether vitamin D therapy with higher doses can improve glucose metabolism needs to be investigated in follow-up trials.

Lipoprotein distribution of a novel endotoxin antagonist, E5531, in plasma from human subjects with various lipid levels.

The purpose of this study was to determine the distribution profile of a novel endotoxin antagonist, [(14)C]E5531, at 1 microg/ml in plasma samples obtained from fasted human subjects with various lipid and protein concentrations. Our findings suggest that the majority of E5531 binds with high-density lipoproteins (HDLs) independently of plasma lipid and protein levels tested. Furthermore, it appears that an increase in triglyceride-rich lipoprotein (TRL) lipid and protein levels and an increase in low-density lipoprotein (LDL) lipid levels significantly increase TRL plus LDL binding of E5531. However, only an increase in HDL protein levels significantly increases HDL binding of E5531.

Plasma lipoprotein distribution of liposomal nystatin is influenced by protein content of high-density lipoproteins.

The plasma lipoprotein distribution of free nystatin (Nys) and liposomal nystatin (L-Nys) in human plasma samples with various lipoprotein lipid and protein concentrations and compositions was investigated. To assess the lipoprotein distributions of Nys and L-Nys, human plasma was incubated with Nys and L-Nys (equivalent to 20 microg/ml) for 5 min at 37 degreesC. The plasma was subsequently partitioned into its lipoprotein and lipoprotein-deficient plasma fractions by step-gradient ultracentrifugation, and each fraction was analyzed for Nys content by high-pressure liquid chromatography. The lipid and protein contents and compositions of each fraction were determined with enzymatic kits. Following the incubation of Nys and L-Nys in human plasma the majority of Nys recovered within the lipoprotein fractions was recovered from the high-density lipoprotein (HDL) fraction. Incorporation of Nys into liposomes consisting of dimyristoylphosphatidylcholine and dimyristoylphosphatidylglycerol significantly increased the percentage of drug recovered within the HDL fraction. Furthermore, it was observed that as the amount of HDL protein decreased the amounts of Nys and L-Nys recovered within this fraction decreased. These findings suggest that the preferential distribution of Nys and L-Nys into plasma HDL may be a function of the HDL protein concentration.

Physical characteristics and lipoprotein distribution of liposomal nystatin in human plasma.

The physical characteristics and lipoprotein distribution of free nystatin (NYS) and liposomal NYS (L-NYS) in human plasma were investigated. To determine the percentage of NYS that was lipid associated following incubation in human plasma, C18 reverse-phase extraction columns were used. To assess plasma drug distribution, NYS and L-NYS (20 microg/ml) were incubated in human plasma for 5, 60, and 120 min at 37 degrees C. After each interval, plasma was removed and separated into its lipoprotein and lipoprotein-deficient plasma (LPDP) fractions by ultracentrifugation and assayed for NYS by high-pressure liquid chromatography. Further studies evaluated the liposome structure of L-NYS by filtering through a 0.14-microm-pore-size microfilter before and after the addition of human plasma. When reconstituted L-NYS (mean particle diameter +/- standard deviation, 321 +/- 192 nm) was applied to a C18 column, 67% +/- 4% of the initial NYS concentration was associated with the lipid. When plasma samples containing L-NYS that had been incubated for 5 to 120 min at 37 degrees C were applied to C18 columns, 66 to 76% of the NYS was lipid associated. Incubation of NYS in human plasma for 5 min at 37 degrees C resulted in 3% +/- 1% of the initial NYS concentration incubated in the low-density lipoprotein (LDL) fraction, 23% +/- 4% of that in the high-density lipoprotein (HDL) fraction, and 66% +/- 10% of that in the LPDP fraction. In contrast, the distribution of NYS following incubation of L-NYS in human plasma for 5 min was 13% +/- 2% in the LDL fraction, 44% +/- 5% in the HDL fraction, and 42% +/- 5% in the LPDP fraction. Similar results were observed following 60 and 120 min of incubation. In addition, the liposome structure of L-NYS was quickly lost when mixed with plasma. These findings suggest that rapid disruption of the L-NYS structure upon incubation in human plasma is consistent with its rapid distribution in plasma. The preferential distribution of NYS into the HDL fraction upon incubation of L-NYS may be a function of its phospholipid composition.

Synchronized scanning of the first and second mass spectrometers on tandem double-focusing mass spectrometers.

A method is described to synchronize the scans of the first and second double-focusing mass spectrometers of a tandem double-focusing mass spectrometer. The scans are synchronized by scanning the first mass spectrometer with voltages instead of the magnetic field. The method is demonstrated with scans that provide all of the precursor ions that produce a selected product ion (precursor ion scan). These precursor ion scans are compared to the previous method of obtaining precursor ion scans on a tandem double-focusing mass spectrometer. The precursor ion scans using the synchronized scanning allow for the use of high-energy collisions on any tandem double-focusing mass spectrometer, while limiting the mass range possible in a single scan. The limited mass range may be corrected by obtaining several spectra with different magnetic fields on the first mass spectrometer.

The primary structure and carbohydrate specificity of a beta-galactosyl-binding lectin from toad (Bufo arenarum Hensel) ovary reveal closer similarities to the mammalian galectin-1 than to the galectin from the clawed frog Xenopus laevis.

The detailed characterization of a galectin from the toad (Bufo arenarum Hensel) ovary in its primary structure, carbohydrate specificity, and overall biochemical properties has provided novel information pertaining to structural and evolutionary aspects of the galectin family. The lectin consists of identical single-chain polypeptide subunits composed of 134 amino acids (calculated mass, 14,797 daltons), and its N-terminal residue, alanine, is N-acetylated. When compared to the sequences of known galectins, the B. arenarum galectin exhibited the highest identity (48% for the whole molecule and 77% for the carbohydrate recognition domain (CRD)) with the bovine spleen galectin-1, but surprisingly less identity (38% for the whole molecule and 47% for the CRD) with a galectin from Xenopus laevis skin (Marschal, P., Herrmann, J., Leffler, H., Barondes, S. H., and Cooper, D. N. W. (1992) J. Biol. Chem. 267, 12942-12949). Unlike the X. laevis galectin, the binding activity of the B. arenarum galectin for N-acetyllactosamine, the human blood group A tetrasaccharide and Galbeta1,3GalNAc relative to lactose, was in agreement with that observed for the galectin-1 subgroup and those galectins having "conserved" (type I) CRDs (Ahmed, H., and Vasta, G. R. (1994) Glycobiology 4, 545-549). Moreover, the toad galectin shares three of the six cysteine residues that are conserved in all mammalian galectins-1, but not in the galectins from X. laevis, fish, and invertebrates described so far. Based on the homologies of the B. arenarum galectin with the bovine spleen galectin-1 and X. laevis skin galectin, it should be concluded that within the galectin family the correlation between conservation of primary structure and phylogenetic distances among the source species may not be a direct one as proposed elsewhere (Hirabayashi, J., and Kasai, K. (1993) Glycobiology 3, 297-304). Furthermore, galectins with conserved (type I) CRDs, represented by the B. arenarum ovary galectin, and those with "variable" (type II) CRDs, represented by the X. laevis 16-kDa galectin, clearly constitute distinct subgroups in the extant amphibian taxa and may have diverged early in the evolution of chordate lineages.

The importance of charge-separation reactions in tandem mass spectrometry of doubly protonated angiotensin II formed by electrospray ionization: Experimental considerations and structural implications.

The occurrence of charge-separation reactions in tandem mass spectrometry of doubly protonated angiotensin II is demonstrated by the use of mass-analyzed ion kinetic energy spectrometry (MIKES) and kinetic energy release distributions (KERDs). Linked scans at a constant B/E severely discriminate against product ions formed by charge-separation reactions. Although the products are significantly more abundant in MIKES experiments, instrumental discrimination still makes quantitation of relative product ion abundances highly inaccurate. The most probable KERs (T m. p.) and the average KERs (T ave.) of the reactions are determined from the KERDs, and these values are compared to the KERs determined from the peak widths at half-height (T 0. 5). The measurement of T 0. 5 is a poor approximation to T m. p. and T ave.. The T m. p. is used to calculate a most probable intercharge distance, which is compared to results from molecular dynamics calculations. The results provide evidence with regard to the mechanisms of fragmentation of multiply charged ions and the location of the charge site in relation to the decomposition reactions.

Isolation and identification of a protoheme IX derivative released during autolytic cleavage of human myeloperoxidase.

Myeloperoxidase (MPO) is a functionally important component of the normal human neutrophil host defense system. This enzyme possesses a dimeric structure composed of two heavy-subunit/light-subunit protomers, with a heme-like prosthetic group covalently linked to each heavy subunit. Although MPO exhibits unusual spectral and enzymatic properties, the nature of the prosthetic group and its mode of linkage with the apoenzyme have not been determined. In an earlier report (K.L. Taylor, J. Pohl, and J.M. Kinkade, Jr. (1992) J. Biol. Chem. 267, 25282-25288), characterization of the autolytic cleavage of MPO led to the proposal that the prosthetic group was covalently linked to the apoenzyme via a methionyl sulfonium bond with Met409. In the present study, we have demonstrated that autolytic cleavage of MPO, followed by protease digestion under nonreducing conditions, effects the release of a macrocycle with visible and Raman spectral properties consistent with that of a protoheme IX derivative. Mass spectrometric analysis, in conjunction with metabolic labeling studies and recent X-ray crystallographic data, have led to the structural assignment of this macrocycle as 1,5-dihydroxymethyl-3,8-dimethyl-4-vinyl-2-(2'-methylthio) ethenylporphine-6,7-dipropionic acid-iron complex. Based on the mechanism of methionyl sulfonium bond cleavage, this structure is consistent with our earlier proposal that the MPO prosthetic group is covalently linked to the enzyme via a methionyl sulfonium bond and suggests that this linkage occurs through a peripheral vinyl substituent.

How to measure the kinetic energy distribution of the precursor ion main beam in mass-analyzed ion kinetic energy spectrometry experiments.

Scans of the electrostatic analyzer (ESA) across the precursor ion beam in reverse-geometry (BE) mass spectrometers that are operated under double-focusing conditions do not measure the "energy resolution of the main beam": They only measure double-focusing resolution. The only way that ESA scans can measure the kinetic energy distribution of the main beam is to operate the instrument so that angular (directional) focusing is not achieved. Thus, the mass spectrometer is no longer double-focusing. Under double-focusing conditions, however, scans of the accelerating voltage while the magnetic field and ESA are held constant can be used to measure either the kinetic energy distribution of the main beam that enters the magnet or the energy-resolving power of the instrument. Scans at a constant ratio of B(2)/E can be used similarly. The energy-resolving power of any ESA is defined by its dispersion and the widths of the energy-resolving object and image slits that immediately precede and follow the ESA, respectively. The use of BE, EB, and triple-sector instruments to measure energy-resolving power and the kinetic energy distribution of the precursor ion main beam is compared and discussed.

Widespread tissue distribution of human chymase.

OBJECTIVE: Human chymase is a potent and specific angiotensin (Ang) II-forming serine proteinase. Although the histological localization of heart chymase indicated that this enzyme contributes to extracellular Ang II formation, the systemic distribution and the level of expression of chymase in various human tissues have not been clarified. This information is needed to elucidate the human tissue Ang II system. METHODS: Levels of immunoreactivity and enzymatic activity in various human tissues were evaluated respectively by Western blot analysis and by an enzymatic assay for Ang II-forming activity from Ang I. RESULTS: High levels of chymase-like immunoreactivity were found in alimentary tract tissue, uterus and tonsil; moderate levels were found in both cardiac ventricles, lung, adenoid and liver; low levels were found in the cardiac atria, coronary artery, aorta and skin; and almost undetectable levels were found in the spleen and kidney. High levels of chymase-like enzymatic activity were detected in skin, oesophagus, stomach and uterus; moderate levels were found in both cardiac ventricles, lung, colon, tonsil, adenoid and renal cortex; and low levels were found in the cardiac atria, coronary artery, aorta, spleen, renal medulla and liver. CONCLUSIONS: Our studies have revealed heterogeneous and widespread tissue distribution of human chymase throughout the human body and indicate that chymase probably has a significant influence not only in the heart but also in other tissues.

Micrometastatic tumour cells in bone marrow of patients with gastric cancer: methodological aspects of detection and prognostic significance.

Monoclonal antibodies (Mab) are potent probes to identify individual tumour cells or small tumour cell clusters in bone marrow. In the present study, various antibodies directed against either cell surface or intracytoplasmic antigens of epithelial cells were assessed for their ability to detect such cells in bone marrow of patients with breast, colorectal and gastric cancer. According to the presented data, monoclonal antibodies against intracellular cytokeratin (CK) components are superior in terms of specificity and sensitivity to antibodies reacting with epitopes of the cell membrane. Using a monoclonal antibody against the cytokeratin polypeptide 18 in connection with the alkaline phosphatase anti-alkaline phosphatase detection system (APAAP), we could detect tumour cells in bone marrow of 34 out of 97 patients with gastric cancer examined at the time of primary surgery. The incidence of positive findings was correlated to established risk factors, such as histological classification and locoregional lymph node involvement. Clinical follow-up studies on 38 patients demonstrated a significantly increased relapse rate in patients presenting with CK-positive cells in their bone marrow at the time of primary surgery. Thus the described technique may help to identify patients with gastric cancer carrying a high risk of early relapse.

Detection of femtomole and sub-femtomole levels of peptides by tandem magnetic sector/reflectron time-of-flight mass spectrometry and matrix-assisted laser desorption ionization.

This article describes results of low-level (sub-femtomole) detection of peptides by matrix-assisted laser desorption ionization. The matrix-assisted laser desorption ionization method can be used for low-level detection of the parent ion, either [M + H](+) or [M + Na](+), and collision-induced dissociation of the parent ion can be performed at the picomole level. The instrument used for these studies is a novel high-performance magnetic sector (electric(E)/magnetic(B) sector)/reflectron time-of-flight (TOP) tandem mass spectrometer (EB/TOF).

Superelastic collisions of electrons with excited Mn(+).

Excited Mn(+) ions formed by electron ionization of Mn2(CO)10 are deexcited in superelastic electron-ion collisions. The ions are held in the trap of a Fourier transform ion cyclotron resonance spectrometer and subjected to bombardment by an electron beam of varying energy. The population of excited Mn(+) ions after exposure to the beam is monitored by examining reaction of the trapped Mn(+) ions with Cr(CO)6. Charge transfer to form Cr(CO) 6 (+) is exothermic and efficient only for excited Mn(+). It is found that deexcitation is read if y observable for electrons with energies less than 2 eV.